Emergent BioSolutions reports after the close today with nearly one-in-five free-float shares already borrowed against it — and a stock that has given up most of its modest month-long gains in a single week.
Short interest is the defining story here. It has climbed to 18.5% of the free float, up 6.2% over the past month in share terms and ticking higher again on Wednesday to around 9.73 million shares. That places EBS in the 89th percentile for short interest on an inverse basis — the ORTEX short score is 68.6, reflecting a stock with a heavily populated bear camp. What is notable is the stability of the position: week-on-week, short interest is essentially flat. Shorts added through April, found a level, and held it. There is no sign of meaningful covering into the print. The borrow market is not tightening to match — availability is close to fully used historically, though current cost-to-borrow is just 0.51%, down 11.5% on the week after a brief spike to 1.22% on April 20. With 13.5 days to cover per FINRA's fortnightly data, any short-side reversal would take time to unwind.
Options traders have shifted more defensive over the past two weeks. The put/call ratio is running at 0.32, above its 20-day average of 0.25 — placing it roughly 1.1 standard deviations elevated — and it has drifted upward steadily from the 0.19 range in mid-April. That move sits closer to the 52-week high of 0.38 than the 52-week low of 0.04. It is not a panicked reading, but it does signal that call-side enthusiasm has cooled meaningfully since mid-month.
The Street view is thin and increasingly cautious. The only active coverage is HC Wainwright, which cut its price target to $12.00 from $15.00 in March — the most recent action, now 52 days old. With the stock at $7.99, that target implies meaningful upside on paper, but the downward revision signals eroding conviction. The bull case rests on 11 government contract modifications secured in 2025 and the biodefense market's long-term growth trajectory toward $32.9 billion by 2034, anchored by BARDA relationships. The bear case is more immediate: NARCAN faces growing generic pressure, government procurement remains lumpy and uncertain, and there are dilution risks on the horizon. Valuation data in the snapshot is drawn from stale fiscal periods and should not be relied upon for current-price comparisons.
The recent earnings track record is a warning. Last February's print sent the stock down 26% on the day and 23% over the following five days. The March 5 event — a full-year results release — produced a further 5.5% one-day loss and 7.3% over five days. Two consecutive large post-earnings drops have trained the market to hedge. That institutional memory explains the options skew and the persistence of the 18.5% short position heading into today's release. Insider activity adds context but not comfort: the CEO, CFO, and multiple SVPs all sold shares at $8.44 on March 5, the same day as the year-end print. The sales were modest in dollar terms — the CEO disposed of $312,744 worth — but the timing and breadth across the management team were notable. Dimensional Fund Advisors added over 500,000 shares as recently as March 31, offering a counterpoint from the institutional side.
Peers offer mixed backdrop. CYTK dropped 10% on the week and ARWR fell 4.6%, while IONS was flat and CPRX gained 8.9% — so there is no clean sector-wide headwind to blame EBS's own 3.6% weekly decline on. The next session will be entirely about whether today's Q1 print can interrupt two straight quarters of double-digit post-earnings selling, and whether BARDA contract momentum translates into anything that moves the bear camp.
See the live data behind this article on ORTEX.
Open EBS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
